SEATTLE, April 20, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused…
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA…
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model…
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical…
Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumorsNEW YORK, April…
Nes-Ziona, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells…
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation…
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosisFirst time efti…
New tissue imaging tool designed to revolutionize clinical researchSOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Standard BioTools…